Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.60 |
| ▸ | GSPT1 | P15170 | 4/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 8/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.42 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461692 | 0.92 | CRBN (0.71) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL7019447 | 0.82 | CRBN (0.58) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL27262164 | 0.80 | CRBN (0.56) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL13815863 | 0.80 | CRBN (0.53) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL27262311 | 0.79 | CRBN (0.60) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL1413830 | 0.78 | CRBN (0.71) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL60871 | 0.78 | CRBN (0.76) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL29285298 | 0.78 | CRBN (0.79) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL30313102 | 0.78 | CRBN (0.83) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL1403564 | 0.77 | CRBN (0.86) | CRBNGSPT1DDB1IKZF3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877780-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885GSPT1 1959/4885DDB1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.